Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 24:2024:4749097.
doi: 10.1155/2024/4749097. eCollection 2024.

Prevalence and Residual Risk of HIV in Volunteer Blood Donors of Zhejiang Province, China, from 2018 to 2022

Hong Zhu  1   2 , Wei Ding  1   2 , Wenjuan Han  1 , Xiaofan Zheng  1 , Yiqing Hu  1 , Jie Dong  1   2 , Yaling Wu  1   2 , Danxiao Wu  1   2 , Jinhui Liu  1   2 , Faming Zhu  1   2
Affiliations

Prevalence and Residual Risk of HIV in Volunteer Blood Donors of Zhejiang Province, China, from 2018 to 2022

Hong Zhu et al. Can J Infect Dis Med Microbiol. .

Abstract

Background: Blood safety levels have been significantly improved since the implementation of nucleic acid amplification technology (NAT) testing for blood donors. However, there remains a residual risk of transfusion transmission infections. This study aimed to evaluate the prevalence of HIV and its residual risk transmission among volunteer blood donors of Zhejiang Province, China, for five years after NAT implementation.

Materials and methods: All specimens and information were collected from voluntary unpaid donors at all blood services in Zhejiang Province, China, from January 2018 to December 2022. The HIV antibody or antigen and HIV RNA were detected using enzyme-linked immunosorbent assay and NAT, respectively. The HIV residual risk transmission was calculated using the incidence or window period model.

Results: A total of 3,375,678 voluntary blood donors were detected, revealing an HIV prevalence of 9.92/100000. The HIV prevalence of blood donors in 12 blood services in Zhejiang Province was 6.11, 6.98, 7.45, 8.21, 8.36, 8.94, 9.04, 9.66, 9.73, 10.22, 11.80, and 12.47 per 100000 donors, without statistically significant difference observed among the services (p > 0.05). The HIV prevalence of males (15.49/100000) was significantly higher compared to females (1.95/100000; p < 0.05). There was an insignificant difference in HIV prevalence among blood donors of all different age groups (p > 0.05), but the HIV prevalence in the 26-35 age group and 18-25 age group was significantly higher compared to the 36-45 age group (p < 0.05). The difference in HIV prevalence between first-time blood donors (13.65/100,000) and repeat blood donors (6.78/100,000) was statistically significant (p < 0.05). From 2018 to 2022, the HIV residual risk in blood transfusion transmission was 0.266/100000.

Conclusion: The prevalence of HIV among blood donors in Zhejiang Province, China, is associated with age, gender, and times of blood donation. The HIV residual risk in blood transfusion transmission remains low in the province, and increasing the rate of repeat blood donors is beneficial to improve blood safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Holcomb J. B., Tilley B. C., Baraniuk S., et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA . 2015;313(5):471–482. - PMC - PubMed
    1. Shi J., Zhou C., Pan W., et al. Effect of high- vs low-dose tranexamic acid infusion on need for red blood cell transfusion and adverse events in patients undergoing cardiac surgery: the OPTIMAL randomized clinical trial. JAMA . 2022;328(4):336–347. doi: 10.1001/jama.2022.10725. - DOI - PMC - PubMed
    1. Carson J. L., Guyatt G., Heddle N. M., et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA . 2016;316(19):2025–2035. doi: 10.1001/jama.2016.9185. - DOI - PubMed
    1. Dean C. L., Wade J., Roback J. D. Transfusion-transmitted infections: an update on product screening, diagnostic techniques, and the path ahead. Journal of Clinical Microbiology . 2018;56(7) doi: 10.1128/jcm.00352-18.e00352-18 - DOI - PMC - PubMed
    1. Lelie N., Busch M., Kleinman S. Residual risk of transfusion-transmitted hepatitis B virus (TT-HBV) infection by NAT-screened blood components: a review of observed versus modeled infectivity from donors with window period and occult HBV infections. Transfusion . 2021;61(11):3190–3201. doi: 10.1111/trf.16675. - DOI - PubMed

LinkOut - more resources